Antirheumatic drugs, B cell depletion and critical COVID-19: correspondence on 'Clinical course of coronavirus disease 2019 (COVID-19) in a series of 17 patients with systemic lupus erythematosus under long-term treatment with hydroxychloroquine' by Mathian et al
- PMID: 32859609
- DOI: 10.1136/annrheumdis-2020-218778
Antirheumatic drugs, B cell depletion and critical COVID-19: correspondence on 'Clinical course of coronavirus disease 2019 (COVID-19) in a series of 17 patients with systemic lupus erythematosus under long-term treatment with hydroxychloroquine' by Mathian et al
Keywords: B-lymphocytes; inflammation; rituximab.
Conflict of interest statement
Competing interests: None declared.
Comment in
-
Response to: 'Antirheumatic drugs, B cell depletion and critical COVID-19: correspondence on 'Clinical course of coronavirus disease 2019 (COVID-19) in a series of 17 patients with systemic lupus erythematosus under long-term treatment with hydroxychloroquine by Mathian et al' by Notz et al.Ann Rheum Dis. 2022 Nov;81(11):e217. doi: 10.1136/annrheumdis-2020-218795. Epub 2020 Nov 25. Ann Rheum Dis. 2022. PMID: 33239273 No abstract available.
Comment on
-
Clinical course of coronavirus disease 2019 (COVID-19) in a series of 17 patients with systemic lupus erythematosus under long-term treatment with hydroxychloroquine.Ann Rheum Dis. 2020 Jun;79(6):837-839. doi: 10.1136/annrheumdis-2020-217566. Epub 2020 Apr 24. Ann Rheum Dis. 2020. PMID: 32332072 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical